Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

BioInvent International AB (BOVNF) Stock Price & Analysis

5 Followers

BOVNF Stock Chart & Stats

$0.29$0.01(2.51%)
At close: 4:00 PM EST
$0.3$0.4$0.5$0.6Nov 2Nov 9
Day’s Range
$0.27 - $0.30
52-Week Range
$0.27 - $3.29
Previous Close
$0.28
Volume
N/A
Average Volume (3M)
588
Market Cap
$19.83M
Enterprise Value
$1.30B
Total Cash (Recent Filing)
$224.56M
Total Debt (Recent Filing)
$19.33M
Price to Earnings (P/E)
―
Beta
0.67
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
-0.11
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

BI-1808 Clinical And Regulatory Progress

BI-1808 has achieved regulatory recognition and encouraging early clinical results across difficult-to-treat cancers. Fast Track status, observed responses, and planned randomized development could improve partnering appeal and support a clearer path toward pivotal testing over the next several quarters.

Multi-program Oncology Pipeline

The pipeline spans multiple antibody immunotherapy programs and cancer settings, reducing reliance on a single clinical asset. Continued BI-1206 readouts and planned BI-1808 studies provide several potential value-creation paths, while partnering can help advance selected programs.

Conservatively Levered Balance Sheet

Very low leverage limits the burden of interest and debt repayment while preserving financial flexibility for a clinical-stage biotech. Although the asset base is shrinking, the conservative capital structure gives management more room to use equity, partnerships, or other funding strategically.

Bears Say

Persistent And Accelerating Cash Burn

Persistent negative operating and free cash flow means BioInvent must continue funding research and clinical operations without internally generated cash. The latest acceleration increases the risk that future development will require additional financing or partnering before programs reach commercial revenues.

Funding Remains Dependent On The Rights Issue

The near-term operating plan depends on completing a rights issue that is not fully covered and remains subject to shareholder approval. Any shortfall could constrain clinical execution, increase reliance on partnering, or force further financing before the pipeline reaches meaningful commercial maturity.

Loss-making And Volatile Revenue Base

Revenue volatility and sustained deep operating and net losses make current earnings capacity difficult to support ongoing development independently. The lower TTM revenue base, combined with widening losses, leaves BioInvent exposed to milestone timing and increases dependence on external capital.

BioInvent International AB News

BOVNF FAQ

What was BioInvent International AB’s price range in the past 12 months?
BioInvent International AB lowest stock price was $0.27 and its highest was $3.29 in the past 12 months.
What is BioInvent International AB’s market cap?
BioInvent International AB’s market cap is $19.83M.
When is BioInvent International AB’s upcoming earnings report date?
BioInvent International AB’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 111 days.
How were BioInvent International AB’s earnings last quarter?
BioInvent International AB released its earnings results on Oct 29, 2026. The company reported -$0.184 earnings per share for the quarter, beating the consensus estimate of -$0.202 by $0.018.
Is BioInvent International AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does BioInvent International AB pay dividends?
BioInvent International AB does not currently pay dividends.
What is BioInvent International AB’s EPS estimate?
BioInvent International AB’s EPS estimate is -0.11.
How many shares outstanding does BioInvent International AB have?
BioInvent International AB has 65,804,360 shares outstanding.
What happened to BioInvent International AB’s price movement after its last earnings report?
BioInvent International AB reported an EPS of -$0.184 in its last earnings report, beating expectations of -$0.202. Following the earnings report the stock price went down -81.478%.
Which hedge fund is a major shareholder of BioInvent International AB?
Currently, no hedge funds are holding shares in BOVNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology